218 related articles for article (PubMed ID: 33707832)
1. Impact of ABCB1 Gene (C3435T/A2677G) Polymorphic Sequence Variations on the Outcome of Patients with Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia in Kashmiri Population: A Case-Control Study.
Baba SM; Pandith AA; Shah ZA; Geelani SA; Mir MM; Bhat JR; Bhat GM
Indian J Hematol Blood Transfus; 2021 Jan; 37(1):21-29. PubMed ID: 33707832
[TBL] [Abstract][Full Text] [Related]
2. Concurrent effects of ABCB1 C3435T, ABCG2 C421A, and XRCC1 Arg194Trp genetic polymorphisms with risk of cancer, clinical output, and response to treatment with imatinib mesylate in patients with chronic myeloid leukemia.
Salimizand H; Amini S; Abdi M; Ghaderi B; Azadi NA
Tumour Biol; 2016 Jan; 37(1):791-8. PubMed ID: 26250462
[TBL] [Abstract][Full Text] [Related]
3. Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients.
Au A; Aziz Baba A; Goh AS; Wahid Fadilah SA; Teh A; Rosline H; Ankathil R
Biomed Pharmacother; 2014 Apr; 68(3):343-9. PubMed ID: 24581936
[TBL] [Abstract][Full Text] [Related]
4. Molecular study of ABCB1 gene and its correlation with imatinib response in chronic myeloid leukemia.
Ben Hassine I; Gharbi H; Soltani I; Ben Hadj Othman H; Farrah A; Amouri H; Teber M; Ghedira H; Ben Youssef Y; Safra I; Abbes S; Menif S
Cancer Chemother Pharmacol; 2017 Oct; 80(4):829-839. PubMed ID: 28836054
[TBL] [Abstract][Full Text] [Related]
5. Influence of CYP3A5*3 and ABCB1 C3435T on clinical outcomes and trough plasma concentrations of imatinib in Nigerians with chronic myeloid leukaemia.
Adeagbo BA; Bolaji OO; Olugbade TA; Durosinmi MA; Bolarinwa RA; Masimirembwa C
J Clin Pharm Ther; 2016 Oct; 41(5):546-51. PubMed ID: 27426203
[TBL] [Abstract][Full Text] [Related]
6. Association of MDR1 gene polymorphism (G2677T) with imatinib response in Egyptian chronic myeloid leukemia patients.
Elghannam DM; Ibrahim L; Ebrahim MA; Azmy E; Hakem H
Hematology; 2014 Apr; 19(3):123-8. PubMed ID: 23683876
[TBL] [Abstract][Full Text] [Related]
7. ABCB1 haplotypes but not individual SNPs predict for optimal response/failure in Egyptian patients with chronic-phase chronic myeloid leukemia receiving imatinib mesylate.
Ali MA; Elsalakawy WA
Med Oncol; 2014 Nov; 31(11):279. PubMed ID: 25301112
[TBL] [Abstract][Full Text] [Related]
8. Impact of ABCB1 Gene Polymorphisms and Smoking on the Susceptibility Risk of Chronic Myeloid Leukemia and Cytogenetic Response.
Mohammadi F; Shafiei M; Assad D; Rostami G; Hamid M; Foroughmand AM
Iran Biomed J; 2021 Jan; 25(1):54-61. PubMed ID: 33129240
[TBL] [Abstract][Full Text] [Related]
9. Do polymorphisms in MDR1 and CYP3A5 genes influence the risk of cytogenetic relapse in patients with chronic myeloid leukemia on imatinib therapy?
Harivenkatesh N; Kumar L; Bakhshi S; Sharma A; Kabra M; Velpandian T; Gogia A; Shastri SS; Gupta YK
Leuk Lymphoma; 2017 Sep; 58(9):1-9. PubMed ID: 28367681
[TBL] [Abstract][Full Text] [Related]
10. Glutathione S-transferase gene polymorphic sequence variations: Association with risk and response to Imatinib among Chronic Myeloid Leukemia patients of Kashmir.
Baba SM; Shah ZA; Pandith AA; Geelani SA; Mir MM; Bhat JR; Gul A; Bhat GM
Int J Lab Hematol; 2021 Oct; 43(5):1000-1008. PubMed ID: 33470551
[TBL] [Abstract][Full Text] [Related]
11. ABCB1 haplotypes are associated with P-gp activity and affect a major molecular response in chronic myeloid leukemia patients treated with a standard dose of imatinib.
Vivona D; Lima LT; Rodrigues AC; Bueno CT; Alcantara GK; Barros LS; DE Moraes Hungria VT; Chiattone CS; DE Lourdes Lopes Ferrari Chauffaille M; Guerra-Shinohara EM
Oncol Lett; 2014 Apr; 7(4):1313-1319. PubMed ID: 24660038
[TBL] [Abstract][Full Text] [Related]
12. ABCB1 polymorphisms correlate with susceptibility to adult acute leukemia and response to high-dose methotrexate.
Ma CX; Sun YH; Wang HY
Tumour Biol; 2015 Sep; 36(10):7599-606. PubMed ID: 25921280
[TBL] [Abstract][Full Text] [Related]
13. Role of ABCB1 C1236T, G2677T, and C3435T genetic polymorphisms in the development of acute leukemia in a Chinese population.
Feng R; Zhang HX; Zhang HG; Zhang CF
Genet Mol Res; 2016 Sep; 15(3):. PubMed ID: 27706688
[TBL] [Abstract][Full Text] [Related]
14. MDR1/ABCB1 gene polymorphisms in patients with chronic myeloid leukemia.
Lardo M; Castro M; Moiraghi B; Rojas F; Borda N; Rey JA; Lazarowski A
Blood Res; 2015 Sep; 50(3):154-9. PubMed ID: 26457282
[TBL] [Abstract][Full Text] [Related]
15. Methylenetetrahydrofolate Reductase Gene C677T and A1298C Polymorphic Sequence Variations Influences the Susceptibility to Chronic Myeloid Leukemia in Kashmiri Population.
Baba SM; Shah ZA; Javaid K; Pandith AA; Rasool J; Geelani SA; Baba RA; Amin S; Mohammad G
Front Oncol; 2019; 9():612. PubMed ID: 31396477
[No Abstract] [Full Text] [Related]
16. Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia.
Harivenkatesh N; Kumar L; Bakhshi S; Sharma A; Kabra M; Velpandian T; Gogia A; Shastri SS; Biswas NR; Gupta YK
Pharmacol Res; 2017 Jun; 120():138-145. PubMed ID: 28330783
[TBL] [Abstract][Full Text] [Related]
17. Effect of ABCB1 (MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects.
Kim KA; Park PW; Park JY
Br J Clin Pharmacol; 2007 Jan; 63(1):53-8. PubMed ID: 16869811
[TBL] [Abstract][Full Text] [Related]
18. Roles of ABCB1 gene polymorphisms and haplotype in susceptibility to breast carcinoma risk and clinical outcomes.
Wu H; Kang H; Liu Y; Tong W; Liu D; Yang X; Lian M; Yao W; Zhao H; Huang D; Sha X; Wang E; Wei M
J Cancer Res Clin Oncol; 2012 Sep; 138(9):1449-62. PubMed ID: 22526155
[TBL] [Abstract][Full Text] [Related]
19. [Effect of MDR1 and CYP3A5 gene polymorphisms on outcomes of patients receiving imatinib treatment for chronic myeloid leukemia].
He Y; Zao X; Wei X
Nan Fang Yi Ke Da Xue Xue Bao; 2018 Jan; 38(1):34-41. PubMed ID: 33177018
[TBL] [Abstract][Full Text] [Related]
20. ABCB1 haplotype is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib.
Vivona D; Bueno CT; Lima LT; Hirata RD; Hirata MH; Luchessi AD; Zanichelli MA; Chiattone CS; Guerra-Shinohara EM
Blood Cells Mol Dis; 2012 Feb; 48(2):132-6. PubMed ID: 22134106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
